Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study

Purpose Apatinib, a new tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, has shown promising efficacy against several solid cancers, but evidence of its efficacy against relapsed and refractory nasopharyngeal carcinoma is limited. We investigated the efficacy and sa...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Invest New Drugs
Egile Nagusiak: Li, Ling, Kong, Fei, Zhang, Lei, Li, Xin, Fu, Xiaorui, Wang, Xinhua, Wu, Jingjing, Zhang, Fangwen, Ren, Liangliang, Zhang, Mingzhi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer US 2020
Gaiak:
Phase II Studies
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7575486/
https://ncbi.nlm.nih.gov/pubmed/32363427
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-00925-2
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak